Diffractaic acid exhibits thioredoxin reductase 1 inhibition in lung cancer A549 cells

Günaydın, Şükran; Sulukoğlu, Emine Karaca; Kalın, Şeyda Nur; Altay, Ahmet; Budak, Harun

doi:10.1002/jat.4505

Cited by 4 publications

(1 citation statement)

References 51 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dose-and time-dependent antiproliferative effects of vulpinic acid (VA) and doxorubicin (DOX), alone and in combination, on breast cancer cell lines were investigated using 2,3-bis(2methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay. The principle underlying the assay is that only living cells have an active metabolism and can convert XTT to purple formazan, which has a maximum absorbance of 490 nm [17,18]. Firstly, the doseand time-dependent antiproliferative effects of DOX and VA alone on MCF-7 cell was investigated.…”

Section: Cell Proliferation Assaymentioning

confidence: 99%

The Combined Effect of Vulpinic Acid and Doxorubicin in Breast Cancer MCF-7 Cells

Kağan Yeniçeri,

Altay

2024

Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi

View full text Add to dashboard Cite

Breast cancer is a major global health problem that imposes a significant social and economic burden on individuals and societies. Chemotherapy, a common treatment approach, often leads to resistance and unwanted side effects, especially in the advanced stages of the disease. This has led to a search for more effective and less toxic anticancer agents. Lichens, which are associations of fungi and algae, are gaining attention for their potential in cancer therapy. Lichens are rich sources of secondary metabolites with diverse biological effects, including anti-tumor properties. In this study, we summarise the combined effects of vulpinic acid (VA), a lichen acid, with doxorubicin, a chemotherapeutic drug, on breast cancer MCF-7 cells. The results of the XTT assay and subsequent Compsyn analysis showed that VA and doxorubicin (Dox), a chemotherapeutic drug, alone exhibited potent anti-proliferative effects in a dose- and time-dependent manner, and interestingly, when used in combination, they produced an antagonistic effect in the same cancer line. These results provide the first example of a study to show what effect the combination of VA and Dox will have on other breast cancer cell lines.

show abstract

Section: Cell Proliferation Assaymentioning

confidence: 99%

The Combined Effect of Vulpinic Acid and Doxorubicin in Breast Cancer MCF-7 Cells

Kağan Yeniçeri,

Altay

2024

Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi

View full text Add to dashboard Cite

show abstract

Antiproliferative, antimigratory, and apoptotic effects of diffractaic and vulpinic acids as thioredoxin reductase 1 inhibitors on cervical cancer

Budak,

Kalın,

Yapça

2023

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Diffractaic acid exerts anti-cancer effects on hepatocellular carcinoma HepG2 cells by inducing apoptosis and suppressing migration through targeting thioredoxin reductase 1

Sulukoğlu,

Günaydın,

Kalın

et al. 2024

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) represents one of the most common malignant tumors worldwide. Due to the limited number of available drugs and their side effects, the development of new chemotherapeutic strategies for HCC treatment has become increasingly important. This study is aimed at investigating whether diffractaic acid (DA), one of the secondary metabolites of lichen, exhibits a potential anticancer effect on HepG2 cells and whether its anticancer effect is mediated by inhibition of thioredoxin reductase 1 (TRXR1), which is a target of chemotherapeutic strategies due to overexpression in tumor cells including HCC. XTT assay results showed that DA exhibited strong cytotoxicity on HepG2 cells with an IC50 value of 78.07 µg/mL at 48 h. Flow cytometric analysis results revealed that DA displayed late apoptotic and necrotic effects on HepG2 cells. Consistent with these findings, real-time PCR results showed that DA did not alter the BAX/BCL2 ratio in HepG2 cells but upregulated the P53 gene. Moreover, the wound healing assay results revealed a strong anti-migratory effect of DA in HepG2 cells. Real-time PCR and Western blot analyses demonstrated that DA increased TRXR1 gene and protein expression levels, whereas enzyme activity studies disclosed that DA inhibited TRXR1. These findings suggest that DA has an anticancer effect on HepG2 cells by targeting the enzymatic inhibition of TRXR1. In conclusion, DA as a TRXR1 inhibitor can be considered an effective chemotherapeutic agent which may be a useful lead compound for the treatment of HCC.

show abstract

Diffractaic acid exhibits thioredoxin reductase 1 inhibition in lung cancer A549 cells

Cited by 4 publications

References 51 publications

The Combined Effect of Vulpinic Acid and Doxorubicin in Breast Cancer MCF-7 Cells

The Combined Effect of Vulpinic Acid and Doxorubicin in Breast Cancer MCF-7 Cells

Antiproliferative, antimigratory, and apoptotic effects of diffractaic and vulpinic acids as thioredoxin reductase 1 inhibitors on cervical cancer

Diffractaic acid exerts anti-cancer effects on hepatocellular carcinoma HepG2 cells by inducing apoptosis and suppressing migration through targeting thioredoxin reductase 1

Contact Info

Product

Resources

About